Clinical Trial

Effectiveness of Cariprazine Monotherapy for Treatment of Major Depressive Disorder

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This trial protocol aims to evaluate the effectiveness and safety of cariprazine monotherapy compared to treatment as usual for major depressive disorder (MDD) in a pragmatic open-label randomized controlled trial (RCT) conducted at Sultan Qaboos University Hospital Department of Behavioral Medicine. The protocol adheres to the guidelines outlined in Good Clinical Practice (GCP) and will be submitted to the Institutional Review Board (IRB) for approval. The trial will assess the efficacy of cariprazine in improving depressive symptoms and overall functioning, as well as its safety profile in patients with MDD.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-06-26.
Trial Details
NCT Number NCT05933538
Lead Sponsor Sultan Qaboos University
Conditions Depressive Disorder, Major
Enrollment 110 participants
Start Date 2024-08
Primary Completion 2030-08 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2023-07-07